Nom du produit:Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate
IUPAC Name:ethyl 4-bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate
- CAS：5775-89-3
- Formule moléculaire：C8H11BrN2O2
- Pureté：95%
- Numéro de catalogue：CM313111
- Poids moléculaire：247.09
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:5775-89-3
- Formule moléculaire:C8H11BrN2O2
- Point de fusion:-
- Code SMILES:O=C(C1=C(Br)C(C)=NN1C)OCC
- Densité:
- Numéro de catalogue:CM313111
- Poids moléculaire:247.09
- Point d'ébullition:
- N° Mdl:MFCD02253803
- Stockage:
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
Column Infos
- Lorlatinib
- Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.
Recherche 
+86 21 5895 0110 
